In the race for an effective and safe vaccine against COVID-19, the world is increasingly closer to a “winning” formula. This is because nine potential vaccines against the new coronavirus (SARS-CoV-2) are in the third and final phase of testing before approval. According to the schedule, preliminary results from many laboratories are expected for the months of October and November. In this scenario, it is already possible to ask how much vaccines will cost.
With the release of the first phase 3 safety and efficacy results, many countries are able to accelerate the vaccine approval steps and issue an emergency use authorization because of the COVID-19 pandemic. Even before the last phase, Russia and China adopted the procedure for their own immunizers.
How much should the vaccine against COVID-19 cost?
Even though there is anxiety about an effective and safe vaccine against coronavirus, for now, there is no formal forecast of sale and much less the price that the immunizer should reach the end consumer. On the other hand, there are a series of millionaire agreements between companies, organizations (such as WHO) and governments that help to understand the price of vaccines against COVID-19.
Johnson & Johnson and AstraZeneca – commercial partner for the vaccine, in development, by the University of Oxford, in the United Kingdom -, for example, committed to sell the respective immunizers developed without profit during the pandemic, which does not necessarily mean that will be cheap and affordable.
In a commercial agreement with the United States, the dose of AstraZeneca is expected to cost about US $ 4 (approximately R $ 22), and two will be needed for complete immunization. European Union countries must pay £ 2.20 per dose of the immunizer (about R $ 15). On the other hand, the Brazilian government released R $ 1.5 billion to purchase the Oxford formula, but this agreement also provides for the transfer of technology to Fiocruz (Fundação Oswaldo Cruz), that is, national production of the compound may take place.
Now, the immunizer developed by Johnson & Johnson pharmacist, Janssen, the average dose will be $ 10 (about $ 55), based on an agreement with the United States government. The advantage is that, so far, research points to the acquisition of immunity against coronavirus from a single dose.
More vaccine agreements
With higher values, Moderna – in partnership with the National Institutes of Health (NIH), the largest biomedical research center in the USA – foresees a value between US $ 32 to US $ 37 (a value from R $ 177 ) per dose. It is already known that two doses will be required for complete immunization.
However, the final value of the immunizer may be different. This is because Moderna’s CEO, Stéphane Bance, has already argued that “we are working with governments around the world and others to ensure that a vaccine is accessible, regardless of ability to pay.”
From a $ 1.95 billion deal with the US to supply 100 million doses, it is possible to estimate that the COVID-19 vaccine from Pfizer and BioNTec will cost around $ 19.50 (about R $ 108) per dose of the immunizer.
In an interview, the CEO of pharmaceutical Sinopharm, Liu Jingzhen, said that the vaccine against COVID-19 should reach the market, still in December, with a cost less than US $ 145 (less than R $ 806), adding the two doses needed for immunization.
If research with the BCG vaccine against COVID-19 shows good results, as the Murdoch Children’s Research Center investigates. This may be one of the most affordable vaccines against COVID-19, as it is widely produced and used, including in Brazil, to prevent serious cases of tuberculosis. In private networks, the immunizer cost approximately R $ 100 a dose, according to data from last year.
Source: Veja, The Guardian and Uol
Did you like this article?
Subscribe your email to Canaltech to receive daily updates with the latest news from the world of technology.